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Efficacy of intraoperative epidural triamcinolone 
application in lumbar microdiscectomy:  
a matched-control study
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OBJECTIVE The purpose of this study was to investigate whether the intraoperative application of an epidural steroid 
(ES) on the decompressed nerve root improves short- and midterm subjective and objective clinical outcomes after 
lumbar microdiscectomy.
METHODS This study was a retrospective analysis of a 2-center database including consecutive cases in which pa-
tients underwent lumbar microdiscectomy. All patients who received ES application (40 mg triamcinolone, ES group) 
were matched by age and sex to patients who had not received ES application (control group). Objective functional im-
pairment (OFI) was determined using age- and sex-adjusted T-scores of the Timed Up and Go (TUG) test. Back and leg 
pain (visual analog scale), functional impairment (Oswestry Disability Index [ODI], Roland-Morris Disability Index [RMDI], 
and health-related quality of life (hrQoL; 12-Item Short Form Health Survey [SF-12] physical component summary [PSC] 
score and EuroQol [EQ-5D index]) were measured at baseline, on postoperative day 3, and at postoperative week 6.
RESULTS Fifty-three patients who received ES application were matched with 101 controls. There were no baseline 
demographic or disease-specific differences between the study groups, and preoperative pain, functional impairment, 
and hrQoL were similar. On postoperative day 3, the ES group had less disability on the RMDI (mean 7.4 vs 10.3, p = 
0.003) and higher hrQoL as determined by the SF-12 PCS (36.5 vs 32.7, p = 0.004). At week 6, the ES group had less 
disability on the RMDI (3.6 vs 5.7, p = 0.050) and on the ODI by trend (17.0 vs 24.4, p = 0.056); better hrQoL, determined 
by the SF-12 PCS (44.3 vs 39.9, p = 0.018); and lower OFI (TUG test T-score 100.5 vs 110.2, p = 0.005). The week 6 
responder status based on the minimum clinically important difference (MCID) was similar in the ES and control groups 
for each metric. The rates and severity of complications were similar, with a 3.8% and 4.0% reoperation rate in the ES 
group and control group, respectively (p = 0.272). There was a tendency for shorter hospitalization in the ES group (5.0 
vs 5.8 days, p = 0.066).
CONCLUSIONS Intraoperative ES application on the decompressed nerve root is an effective adjunct treatment that 
may lower subjective and objective functional impairment and increase hrQoL in the short and intermediate term after 
lumbar microdiscectomy. However, group differences were lower than the commonly accepted MCIDs for each metric, 
indicating that the effect size of the benefit is limited.
■ CLASSIFICATION OF EVIDENCE Type of question: therapeutic; study design: retrospective cohort trial; evidence: 
Class II.
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Low-back pain (LBP) and irradiating leg pain sec-ondary to lumbar disc herniation (LDH) are gener-ally thought to result from both mechanical pres-
sure on the nerve roots and inflammatory response.35,46 
While surgical removal of the herniated nucleus pulposus 
is effective in alleviating local pressure, the inflammatory 
mediators remain for days to weeks after the procedure.9 
As a result of this, poorly controlled postoperative pain 
delays mobilization and the start of physiotherapy, thereby 
prolonging hospitalization and diminishing hope for re-
covery.43
Epidural steroid (ES) application during lumbar disc-
ectomy was first reported by Jones and Barnett in 1955.28 
They instilled 25–50 mg of hydrocortisone in 50 patients 
and compared their outcomes with the outcomes of 50 
patients who did not receive this treatment. The patients 
in the ES group showed a 40% reduction in use of opi-
ate drugs and could be mobilized earlier. These prom-
ising results stimulated further investigation. With the 
ongoing development and validation of reliable generic 
and disease-specific measures of pain, functional impair-
ment, and health-related quality of life (hrQoL), the effect 
of ES application during lumbar spine surgery has been 
reinvestigated.3,25–27,32,34,37,43,44,46 In a recent systematic re-
view, evidence suggested that intraoperative ES applica-
tion is effective in reducing pain in the early period up 
to 2 weeks postoperatively, whereas the effectiveness in 
the intermediate (2 weeks to 2 months) and longer term 
(> 2 months) was rather weak.26 In these studies, subjec-
tive measures of disability were used, as standardized ob-
jective measures of function have been introduced only 
recently.15,16 In addition, the heterogeneous study designs 
make it difficult to derive firm conclusions concerning 
the effectiveness of intraoperative ES application.26 In 
view of this controversial debate,5,26 more studies using 
validated subjective and objective outcome measures are 
warranted.
Therefore, the present study aimed to investigate wheth-
er the direct application of ES on the decompressed nerve 
root during lumbar microdiscectomy improves objective 
functional impairment (OFI) and subjective clinical out-
come.
Methods
A retrospective review of a prospective, IRB-approved 
2-center database from 2 tertiary Swiss teaching hospitals 
was performed. Consecutive patients undergoing micro-
discectomy for unilateral LDH between September 2013 
and December 2015 were included.
Null Hypothesis and Calculation of Sample Size
The primary null hypothesis was that patients receiving 
ES application during lumbar discectomy (ES group) have 
similar OFI as patients without ES (control group). A sec-
ondary null hypothesis was formulated concerning equal-
ity of subjective pain, functional impairment, and hrQoL 
outcome. As no prior data concerning OFI are available, 
sample size calculations were based on the Oswestry Dis-
ability Index (ODI). Aljabi et al.3 reported 1-month ODI 
values of 34.1 and 42.6 for ES and control groups, respec-
■ CLASSIFICATION OF EVIDENCE
Type of Question Therapeutic
Study Design Retrospective Cohort Trial
Evidence Class II
Stienen and his associates have made an important contribu-
tion to the neurosurgical literature with the publication of this 
retrospective cohort trial using registry data from 2 Swiss 
hospitals. The authors examine whether the intraoperative 
administration of epidural triamcinolone following single-level 
lumbar microdiscectomy improves objective functional impair-
ment (OFI) as measured by the Timed Up and Go test (their 
primary outcome), back and leg pain, disability, and quality 
of life, without increasing the complication rate. Although this 
study has been scrupulously executed, there are some poten-
tially important preoperative differences between the treat-
ment groups with respect to smoking, work status, degree 
of employment, ASA score (American Society of Anesthesi-
ologists physical status classification), and the presence of 
motor deficits. None of these differences achieves statistical 
significance, but many may be clinically important, and the 
presence of multiple imbalances raises the concern that ad-
ditional unmeasured but prognostically important differences 
might be present. In addition, the authors do not disclose 
whether their primary end point was determined by masked 
assessors. Although the Timed Up and Go test is a relatively 
objective end point, observer expectation bias remains pos-
sible in the absence of masked outcome assessment. Finally, 
the authors matched (by age and sex) patients who received 
and did not receive epidural steroid (ES) application, exclud-
ing 35 (18.5%) of 189 potentially eligible patients from their 
trial. This process introduces an opportunity for selection bias 
and decreases the generalizability of the study results. Most 
importantly, although the authors demonstrated statistically 
significant differences in outcome between the ES and control 
treatment groups, none of the prespecified outcome mea-
sures differed by more than the minimum clinically important 
difference established for each of those measures. Integrating 
statistical and clinical significance, and factoring in the addi-
tional possibility that ES application could be associated with 
more complications than no ES application (OR 1.94, 95% CI 
0.26–14.18, p = 0.51), the correct (and important) conclusion 
to draw from the current study is that epidural triamcinolone 
application may improve 6-week OFI, but it may be associ-
ated with an increased risk of infectious complications, so 
additional adequately powered and well-designed trials are 
essential before adopting this intervention into routine prac-
tice. Stienen and colleagues provide essential information 
about the potential effect size of this intervention and about 
what outcome measures should be used. 
— Michael Glantz, MD
Hershey Medical Center 
Hershey, Pennsylvania
Intraoperative epidural steroid application in microdiscectomy
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tively. Given a standard deviation of 10, a sample size of 
40 patients (20 patients in each arm) was required to dem-
onstrate a statistically significant difference with a power 
of 80% and alpha set at 0.05.
Data Collection
The database comprised general patient data (age, sex, 
body mass index [BMI], smoking, and working status), co-
morbidity and anesthesiology risk (Charlson Comorbidity 
Index [CCI]6 and American Society of Anesthesiologists 
[ASA] physical status classification29), and radiological 
markers of degeneration (Modic38 and Pfirrmann42).
OFI was determined using the Timed Up and Go 
(TUG) test with results standardized for age and sex.15,19,50 
The TUG is a timed test that assesses some of the most 
basic but important functions of patients with lumbar de-
generative disc disease, such as standing up, walking (as 
fast as possible), turning around, walking again, and sit-
ting back down. For the TUG measurements, we used a 
specifically designed “TUG app” that is available for free 
download from the Apple and Google app stores. Preop-
erative LBP and irradiating leg pain were rated on a visual 
analog scale (VAS) from 0 to 10. Subjective functional 
impairment was measured by the Roland-Morris Disabil-
ity Index (RMDI; from 0 [no disability] to 24 [severe dis-
ability]) and the ODI (from 0% [no disability] to 100% 
[severe disability]).13,45 The hrQoL measures comprised 
the generic metrics 12-Item Short Form Health Survey 
(SF-12; physical component summary [PCS] score stan-
dardized to a mean of 50) and EQ-5D (EuroQoL Group; 
from −0.074 [worst hrQoL] to 1.00 [best hrQoL], using 
European norms).12
Outcome measurements using all metrics were ob-
tained at baseline, as well as on postoperative day 3 and 
at week 6. Complications up to 30 days after surgery were 
classified according to Landriel Ibanez et al.30 Addition-
ally, length of hospitalization was recorded.
Surgical Intervention
All patients underwent surgery in a knee-chest position 
under general anesthesia and received a single 2-g dose 
of intravenously administered cefazoline (Kefzol, Teva 
Pharma AG) preoperatively as antibiotic prophylaxis. Af-
ter fluoroscopic confirmation of the correct level, patients 
were prepared and draped in the usual sterile fashion. A 
midline skin incision of 2.5–4 cm was made for single-
level surgery. Scissors or monopolar cautery were used 
for fascia opening. The paravertebral musculature was 
scraped from the laminae using a Cobb elevator. Follow-
ing a superior laminotomy, performed with a high-speed 
drill under microscopic view, the ligamentum flavum was 
partially resected, and the interlaminar window was ex-
tended laterally and inferiorly using Kerrison punches. 
Sequestrectomy was followed by partial microdiscectomy 
if considered necessary. Following copious irrigation and 
hemostasis, 40 mg of triamcinolone (Kenacort, Bristol-
Myers Squibb) was applied to the epidural space of the 
decompressed nerve root at the discretion of the surgeon. 
Patients were not aware of whether the steroid medica-
tion was applied. Drains were only inserted in the event of 
unsatisfactory hemostasis. The wound was closed in the 
usual fashion using subcutaneous sutures.
Study Groups
All patients who had received ES application (ES 
group) were matched for age and sex in a 1:2 fashion with 
controls who had not received ES application.
Statistical Considerations
The independent variables were OFI (TUG test), pain 
(VAS back and leg pain), subjective functional impair-
ment (RMDI and ODI), and hrQoL measures (SF-12 
PCS and EQ-5D). Categorical variables (presented as fre-
quency and percentage) were tested for imbalance using 
Pearson chi-square tests. Nominal variables (presented as 
mean and SD) were compared using Student t-tests. The 
responder status to surgical treatment was defined using 
previously published minimum clinically important dif-
ference (MCID) values for OFI of 3.4 seconds,21 ODI 
of 12.8, RMDI of 5.0, SF-12 PCS of 4.9, and EQ-5D of 
0.359.7,48,51 The effect size of the relationship between ES 
application and the week 6 responder status was estimated 
using logistic regression analysis. No stepwise or other 
automated variable selections were used because of their 
well-known limitations.39
The software used for statistical analysis was Stata v14 
(StataCorp LP); p ≤ 0.05 was considered statistically sig-
nificant.
Ethical Considerations
The study was in accordance with the Code of Ethics of 
the World Medical Association (Declaration of Helsinki) 
and was approved by the local institutional review boards 
(University Hospital Geneva and Cantonal Hospital St. 
Gallen). All patients gave written informed consent.
Results
Of 377 patients in the database, 189 with LDH undergo-
ing microdiscectomy without surgical fusion were found 
to be eligible for study inclusion. Of these, 53 patients had 
received ES application as described above (ES group). 
They were matched in a 1:2 ratio for the variables age and 
sex with 101 controls who underwent a similar operation 
without ES application. The combined cohort had a mean 
age of 46.9 years (SD 11.6), and 63.6% of the patients were 
male. There were no significant baseline demographic 
(Table 1) or disease-specific differences (Table 2) between 
the study groups. Table 3 summarizes the similar pain 
levels, subjective and objective impairment, and hrQoL 
before surgery in patients from the ES and control groups.
Figure 1 depicts longitudinal measures of subjective 
and objective functional impairment and hrQoL. At day 3, 
there was no significant difference between the ES group 
(T-score 127.4, 43.6) and the control group (T-score 129.0, 
38.2) in terms of OFI. On the subjective metrics, the ES 
group had less disability on the RMDI (7.4 vs 10.3, p = 
0.003) and higher hrQoL on the SF-12 PCS (36.5 vs. 32.7, 
p = 0.004). There was a tendency for less disability on the 
ODI for the ES group (30.9 vs. 36.5, p = 0.095). At week 
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6, patients of the ES group scored significantly lower than 
those in the control group for OFI (T-score 100.5, 10.0 
vs 110.2, 12.8, p = 0.005). They had less disability on the 
RMDI (3.6 vs 5.7, p = 0.050) and on the ODI by trend (17.0 
vs 24.4, p = 0.056), and better hrQoL determined by the 
SF-12 PCS (44.3 vs 39.9, p = 0.018).
The MCID-based week 6 responder status was similar 
in the ES and control groups on each metric (Table 4). 
With respect to OFI, patients in the ES group were 0.69 
times as likely as patients in the control group to be week 
6 treatment responders (95% CI 0.22–2.14, p = 0.518).
The rates and severity of complications were similar 
in the 2 groups (Table 5), with 3.8% and 4.0% rates of re-
peat surgery (complication type 2b) in the ES and control 
groups, respectively (p = 0.272). Patients in the ES group 
were 1.94 times as likely as those in the control group 
to experience a surgical-site infection (OR 1.94, 95% CI 
0.26–14.18, p = 0.513; 3.8% vs 2.0%). There was a tenden-
cy for shorter duration of hospitalization in the ES group 
(5.0 vs 5.8 days, p = 0.066).
Discussion
In patients with LDH, early biopsy and autopsy find-
ings of compressed and irritated, edematous posterior 
nerve roots revealed inflammatory changes,8 which laid 
out the rationale for adding ES during lumbar disc sur-
gery. Steroids are potent suppressors of inflammatory 
mediators, such as prostaglandins, leukotrienes, bradyki-
nins, and histamines.2 In line with this pathophysiological 
concept, ES application has been shown to be associated 
with reduced pain due to reduction of nerve root edema 
and inflammation.22,35 The majority of previous reports 
were based on retrospective data and compared length of 
hospitalization, day of first mobilization, and use of mild/
strong pain medication, among other proxies of pain and 
disability.1,8,14,28,31,36,37,40,44 Despite a paucity of prospective 
studies reporting a benefit and considerable variability in 
outcome, about half of North American neurosurgeons 
TABLE 1. Comparison of basic characteristics of patients in the 
ES and control groups
Variable
ES Group  
(n = 53)
Controls  
(n = 101)
p  
Value
Mean age in yrs (SD) 45.8 (13.6) 47.5 (10.4) 0.376
Sex 0.654
 Male 35 (66.0) 63 (62.4)
 Female 18 (34.0) 38 (37.6)
Mean BMI in kg/m2 (SD) 26.2 (4.4) 27.5 (4.5) 0.103
Smoking 0.225
 Yes 22 (41.5) 32 (31.7)
 No 31 (58.5) 69 (68.3)
Work status 0.060
 Full-/part-time 32 (60.4) 79 (78.2)
 Not working 13 (24.5) 16 (15.8)
 Disabled 3 (5.7) 4 (4.0)
 Retired 5 (9.4) 2 (2.0)
Mean degree of employ-
ment (SD)*
68.1% (47.1%) 78.9% (38.9%) 0.153
Morphine use 0.807
 No 40 (75.5) 78 (77.2)
 Yes 13 (24.5) 23 (22.8)
ASA 0.245
 0–1 14 (26.4) 36 (35.6)
 2–3 39 (73.6) 65 (64.4)
CCI 0.605
 0–1 50 (94.3) 93 (92.1)
 ≥2 3 (5.7) 8 (7.9)
Data are presented as number of patients (%) unless otherwise indicated.
* In employed patients, percentage relative to full-time employment.
TABLE 2. Comparison of preoperative disease-specific data in 
the ES and control groups
Variable ES Group (n = 53) Controls (n = 101) p Value
Levels 0.688
 1 level 52 (98.1) 98 (97.0)
 ≥2 levels 1 (1.9) 3 (3.0)
Segment 0.730
 L2–3 — (0.0) 1 (1.0)
 L3–4 7 (13.2) 11 (10.9)
 L4–5 20 (37.7) 45 (44.6)
 L5–S1 26 (49.1) 44 (43.6)
Modic changes* 0.598
 No 20 (41.7) 44 (46.3)
 Yes 28 (58.3) 51 (53.7)
Pfirrmann degree* 0.592
 Low (0–3) 24 (50.0) 43 (45.3)
 High (4–5) 24 (50.0) 52 (54.7)
Motor deficit 0.297
 No 39 (73.6) 66 (65.4)
 Yes 14 (26.4) 35 (34.7)
Data are presented as number of patients (%).
* Available in 143 (92.9%) of 154 patients with preoperative MRI data.
TABLE 3. Subjective measures of pain, functional disability, and 
hrQoL in patients scheduled for lumbar microdiscectomy with or 
without ES application
Measure ES (n = 53) No ES (n = 101) p Value
VAS, back pain 3.7 (2.8) 3.5 (2.6) 0.624
VAS, leg pain 5.7 (2.5) 5.0 (2.6) 0.119
RMDI 12.4 (5.3) 12.8 (4.8) 0.618
ODI 50.2 (19.4) 53.7 (17.6) 0.271
EQ-5D index   0.435 (0.218)   0.501 (0.213) 0.080
SF-12 PCS 30.8 (7.9) 29.9 (7.3) 0.491
SF-12 MCS 39.7 (9.3) 41.6 (12.2) 0.316
OFI T-score 132.3 (35.6) 143.7 (55.7) 0.182
MCS = mental component score.
Data are presented as mean (SD).
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use ES application in lumbar disc surgery on a regular ba-
sis.5 Given that the other half do not use ES application, 
its efficacy is still a matter of controversy.26 Recent me-
ta-analyses highlight the need for studies with validated 
outcome measures at fixed time intervals.26,43 The present 
data provide robust estimates of the treatment effect of ES 
application during lumbar microdiscectomy on a compre-
hensive panel of validated subjective and objective generic 
and disease-specific outcome measures of pain, functional 
impairment, and hrQoL. The data show a small but sta-
tistically significant benefit for patients in the ES group, 
both at 3 days and at 6 weeks after surgery, with similar 
complication rates in the ES and control groups.
The credibility of the observations is substantiated by 
internal consistencies both within and between outcome 
measures, as well as by validity between actual observed 
and theoretically expected improvements conferred 
through the use of the tested intervention. Internal con-
sistency is evident within the reduction of pain, objective 
and subjective functional impairment, and improvement 
in hrQoL. Each of these outcome measures demonstrat-
ed improved results in the ES group compared with the 
matched control group, commencing at day 3 and per-
sisting to week 6. Validity (expected compared with ob-
served) can be appreciated at 2 levels. Surgery leads to 
marked improvement on all analyzed metrics, indepen-
dent of the study group. This improvement was graduated, 
being measurable at day 3 and more substantial at week 
6 follow-up. It corresponds to the typical postoperative 
course after lumbar microdiscectomy, lending credibility 
to the observed group differences. The second level of va-
lidity pertains to patient performance by group. Based on 
the previous literature, it could be expected that if a group 
difference was observed, this difference would be in favor 
of the intervention and measurable on several of the ap-
plied outcome metrics.
Objective Functional Outcome
Our results are in line with those of Jones and Barnett, 
who demonstrated a 40% reduction in the need for post-
operative opiate injections in a cohort of 50 lumbar disc-
ectomy patients receiving 25–50 mg of hydrocortisone 
epidurally as early as 1955. The authors also reported on 
FIG. 1. Longitudinal measures of subjective (A) and objective (B) func-
tional impairment and hrQoL (C) in patients who underwent lumbar 
microdiscectomy with or without ES. The x-axes represent the 3 time 
points at which measurements were obtained: preoperatively (Preop), 
postoperative day 3 (D3), and postoperative week 6 (W6). Data are pre-
sented as group means with 95% confidence intervals (error bars). The 
OFI T-scores are adjusted for age and sex. *p ≤ 0.05; **p ≤ 0.005.
TABLE 4. Univariate analysis of the effect size describing the 
relationship of ES application to responder status 6 weeks after 
microdiscectomy
Variable
Univariate Analysis
OR 95% CI p Value
VAS, back pain 1.05 0.32–3.39 0.940
VAS, leg pain 2.88 0.71–11.6 0.138
RMDI 1.46 0.59–3.62 0.416
ODI 1.60 0.51–5.01 0.419
EQ-5D index 1.56 0.66–3.68 0.312
SF-12 PCS 2.55 0.85–7.69 0.096
OFI 0.69 0.22–2.14 0.518
TABLE 5. Rates and severity of complications within 30 days of 
surgery
Complication* ES Group (n = 53) Controls (n = 101) p Value
None 51 (96.2) 91 (90.1)
0.272Grade 1a — (0.0) 6 (5.9)
Grade 2b 2 (3.8) 4 (4.0)
Data are presented as number of patients (%).
* According to the classification of Landriel Ibañez et al.30
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ambulation on postoperative day 3, which was resumed in 
90% of the patients who received ES treatment, compared 
with only 40% of the control group.28 More than 60 years 
later, patients are generally mobilized much earlier as a re-
sult of the development of less invasive microscopic proce-
dures. In addition, more sophisticated tools to objectively 
measure functional outcomes after lumbar disc surgery 
have been established.16 In the present study, the TUG test 
was used to measure OFI.50 This test involves some of the 
functions most relevant to maintaining good quality of life 
for patients with lumbar degenerative disc disease, namely 
standing up, walking, changing direction, and sitting down 
again.15,16 Results are presented as T-scores, standardized 
for age and sex using normal population data.19 Our results 
clearly show that OFI at week 6 was lower in the ES group 
than in the control group. For the first time, these findings 
demonstrate that lower pain and subjective perception of 
disability and higher hrQoL due to ES use also translate 
into objectively measurable lower functional impairment. 
It is important to note that OFI was similar in the early 
postoperative period (day 3); this is explained by acute 
wound pain (LBP), which was shown to influence OFI 
most at day 3.18 This acute pain, originating from muscular 
damage and osteo-ligamentous manipulation, is less influ-
enced by ES application.
Subjective Patient-Reported Outcomes
With respect to subjective outcomes, there are 2 re-
views addressing the efficacy of ES application for pain re-
duction in patients undergoing lumbar discectomy.26,43 The 
more recent review reported a significant pain reduction 
with ES application in 9 (82%) of 11 trials in the early post-
operative period (0–2 weeks), in 4 (57%) of 7 trials in the 
intermediate period (2 weeks–2 months), and in 2 (25%) of 
8 trials in the late period (> 2 months). Thus, the evidence 
in support of intraoperative ES application reducing early 
postoperative pain can be considered strong, while for the 
intermediate period, it can be considered weak, and for the 
late period, the evidence against benefit for ES application 
is relatively strong.26 On the VAS for LBP and irradiating 
leg pain, we did not observe significant differences at day 
3 and week 6 (data not shown).
It is commonly accepted that the use of multidimen-
sional disease-specific questionnaires to estimate func-
tional outcome of spine surgery is superior to the use of 
pain-intensity measures alone.11 However, so far only a few 
studies exploring the effect of ES agents have integrated 
multidimensional outcome measures of function. Aljabi 
et al. randomly assigned patients with unilateral LDH to 
local application of either a sponge soaked in a steroid 
medication or a sponged soaked in normal saline solution 
at the end of the operative procedure.3 The authors dem-
onstrated a statistically significant reduction of the ODI at 
1 week (41.3 vs 54.2, p = 0.014) and 1 month after surgery 
(34.1 vs 42.6, p = 0.004) in favor of the ES group. Also, 
by using the ODI, Shin et al. showed a small but statisti-
cally significant advantage for the ES group 1 week after 
percutaneous endoscopic lumbar discectomy (20.7 vs 27.0, 
p < 0.01).46 As in our study (Table 4), the absolute differ-
ences between the study groups in the reports by Aljabi 
et al. and Shin et al. were below the 12.8-point MCID of 
the ODI.3,46 Finally, Jirarattanaphochai et al. used the ODI 
in a prospective randomized study including patients un-
dergoing microdiscectomy, lumbar decompression, and 
surgical fusion.27 The authors found no significant group 
difference in the ODI at 1 or 3 months after surgery (group 
means were not reported). Similarly, Lundin et al.34 found 
no significant difference on the 12-item Disability Rating 
Index while evaluating physical function in patients ran-
domized to perioperative steroid treatment (including ES 
application) or placebo (normal saline solution). No previ-
ous study used the RMDI to measure the functional out-
come after intraoperative ES application; on this metric 
we found superior results in the ES group (Fig. 1A).
Concerning hrQoL, Hurlbert et al. first demonstrated 
in a prospective randomized approach that patients who 
received an analgesic epidural paste containing methyl-
prednisolone and morphine had more favorable general 
health status at week 6, as determined by the mean SF-36 
score.25 In 2007, Jirarattanaphochai et al. showed that SF-
36 scores were consistently higher in the ES group than in 
the control group. However, this difference was significant 
only in the vitality and mental function subscales.27 We 
used the SF-12 questionnaire to calculate the summary 
score for physical health (PCS). At day 3 and week 6, the 
ES group scored higher on this metric (Fig. 1C), and the 
mean group difference was close to the MCID (Table 4). 
We are not aware of prior studies that used the EQ-5D, but 
although postoperative improvement was seen on this met-
ric for both groups, the questionnaire performed poorly in 
differentiating between the ES and the control group.
Safety of ES Application
Concerns about the safety of ES application have been 
raised by authors of smaller series, in particular with re-
spect to deep infections and epidural abscess formation.2,33 
As early as the 1980s, Delaney et al.10 demonstrated in an 
experimental model that epidural triamcinolone did not re-
sult in significant histological changes and that histologi-
cal findings were in fact comparable to those in controls. 
A recent systematic literature review analyzing the data 
of 1933 patients (742 of whom received ES application) 
revealed similar overall complication rates in patients with 
and without ES application (risk ratio [RR] 1.94, 95% CI 
0.72–5.26, p = 0.19; including infection, arachnoiditis, 
recurrent LDH, durotomy, and cerebrospinal fluid leak). 
With respect to infectious complications, a nonsignifi-
cant trend toward more infections in patients receiving 
ES application was noted (RR 4.58, 95% CI 0.75–27.95, 
p = 0.10).2 Our present findings are in line with those of 
Akinduro et al.,2 as the rates and severity of postopera-
tive complications were similar in both groups (Table 5) 
despite a nonsignificant trend toward more surgical-site 
infections in the ES group. There was no higher rate of 
wound healing problems (minor, not requiring revision 
surgery; Landriel Ibañez Grade 1) in the ES group (Table 
5).30 The second concern pertains to impaired healing of 
the annulus fibrosus by steroid-induced inhibition of fibro-
plasia potentially resulting in more frequent recurrences.46 
As only complications within 30 days of surgery were 
recorded in the present study, the matter of late compli-
cations, such as slow infections or recurrences, cannot be 
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addressed. The findings of Rasmussen et al., who provided 
a 2-year follow-up of 99 patients in each group, with and 
without ES application, demonstrate similar rates of recur-
rent LDH surgeries (7% vs 8%, p > 0.99; in each, 2 patients 
for recurrence), which speaks against a strong negative ef-
fect of ES application.44
Strengths and Limitations
This study is a retrospective analysis of prospectively 
collected data from 2 centers in different language areas 
(German and French), which helps to generalize the find-
ings to a broader population. No significant differences 
in potential confounders, such as age,20 sex,17 and BMI,47 
were present, which eliminates bias with respect to the pri-
mary and secondary outcomes. As the subjective percep-
tion of pain is influenced by physiological, sensory, affec-
tive, cognitive, sociocultural, and behavioral factors, this 
study included a validated objective measure of function.19 
Simple but robust statistical approaches were chosen, re-
ferring not only to statistical significance, but also to the 
clinical relevance of the effect. A placebo effect is unlikely 
to be present in this study as patients were blinded with 
respect to the study intervention.
Because this was not a randomized study, selection bias 
does apply and the above-mentioned limitations of previ-
ous retrospective studies apply to the present work as well. 
Surgeons were more likely to use ES application in cases 
requiring more mechanical manipulation of the nerve root, 
which potentially leads to an underestimation of the treat-
ment effect. The rationale for an MCID-based definition 
of treatment response is to assess whether patients notice 
a clinically meaningful improvement.21 This definition of 
treatment response, however, assumes stability of other 
variables that might factor into the outcome. It should be 
pointed out that the true positive effect of ES application 
on the clinical outcomes might be underestimated, as the 
use of postoperative (opioid) analgesics was not standard-
ized and has been reported to be lower in patients who 
had received ES treatment.2 On the other hand, ES appli-
cation was not used in patients with diabetes or in cases 
where epidural hemorrhage required insertion of a drain, 
and this could lead to an overestimation of the treatment 
effect. Only outcomes up to 6 weeks after surgery were 
considered, which could mask the long-term effects of epi-
dural ES application. However, recent studies show that 
most improvement after noninstrumented microscopic 
spine surgery can be expected within the first 6 weeks.24,48 
Also, long-term effects of ES application, such as a reduc-
tion of epidural scar formation, could not be confirmed.23 
Previous studies almost unequivocally disproved long-
term (i.e., > 6 weeks postoperative) effectiveness of intra-
operative ES application.9,25,26 Comparing return-to-work 
rates in patients with and without ES treatment would have 
been desirable,4,52 but these data were not available. Final-
ly, with regard to the current literature, dosage and types 
of steroids varied considerably, as did surgical techniques 
and postoperative care, rendering comparison with our re-
sults difficult.26
Implications for Clinical Practice
Integrating the present findings and the available litera-
ture on this subject, it appears that removing the sequester 
as the cause of the lumbar nerve root compression is by 
far the most important factor in achieving symptomatic 
relief.27,31 There is good evidence that ES application can 
significantly reduce the use of early postoperative opioid 
analgesic use, and potentially leads to lower incidences of 
oversedation, respiratory depression, constipation, ileus, 
and other adverse effects linked to opioids.2,49 The addi-
tion of ES likely reduces pain and functional impairment 
and increases patients’ hrQoL after microdiscectomy for 
LDH, at least in the first weeks following the procedure. 
The effect size of this adjunct was found to be below the 
MCID in all studies, including the present one. Thus, the 
effect might not translate into a clinically meaningful one. 
However, in view of the weaknesses of previous studies 
and the present one, as discussed above, the true benefit 
of ES application might in fact be underestimated. Studies 
consistently report better or similar outcomes for the group 
receiving ES, whereas no study so far has reported worse 
outcomes, although publication bias might be present.43 ES 
might not come without risk, and as the use of ES after 
lumbar discectomy has been linked with higher infection 
rates by trend,2 we do not recommend its use in patients 
with diabetes or those who are immunocompromised. In 
the absence of robust data on this aspect, some authors—
including us—recommend not using ES in cases of duroto-
my during surgery, as arachnoiditis and neurotoxic effects 
have been reported.2,41 Considering the reduced hospital-
ization time, the relatively low cost of the applied steroid 
may be ameliorated by reduced overall costs. Taking into 
consideration the probable benefit with the potential draw-
backs in mind, we propose to include ES application in the 
preoperative informed consent.
Conclusions
Intraoperative epidural application of steroids on the de-
compressed nerve is an effective treatment adjunct to lower 
subjective and objective functional disability and increase 
hrQoL in the short- and midterm after lumbar microdisc-
ectomy. However, observed differences were lower than 
the commonly accepted MCIDs of each outcome metric, 
indicating that the effect size of the benefit is limited. As 
some data suggest an increased rate of surgical-site infec-
tions, risks and benefits need to be carefully weighed and 
the intervention should at best be discussed with the patient 
when obtaining informed consent.
Acknowledgments
We thank Dr. Marco V. Corniola and Cornelia Lüthi (study 
nurse) for helping to collect the outcome data.
References
 1. Abrishamkar S, Rafiei AR, Sabouri M, Moradi S, Tabesh 
H, Rahmani P, et al: The effect of impregnated autogenous 
epidural adipose tissue with bupivacaine, methylprednisolone 
acetate or normal saline on postoperative radicular and low 
back pain in lumbar disc surgery under spinal anesthesia; a 
randomized clinical trial study. J Res Med Sci 16:621–626, 
2011
 2. Akinduro OO, Miller BA, Haussen DC, Pradilla G, Ahmad 
M. N. Stienen et al.
J Neurosurg Spine Volume 28 • March 2018298
FU: Complications of intraoperative epidural steroid use in 
lumbar discectomy: a systematic review and meta-analysis. 
Neurosurg Focus 39(4):E12, 2015
 3. Aljabi Y, El-Shawarby A, Cawley DT, Aherne T: Effect of 
epidural methylprednisolone on post-operative pain and 
length of hospital stay in patients undergoing lumbar micro-
discectomy. Surgeon 13:245–249, 2015
 4. Asher AL, Chotai S, Devin CJ, Archer-Swygert K, Parker SL, 
Bydon M, et al: Predictive model for return to work after elec-
tive surgery for lumbar degenerative disease: an analysis from 
National Neurosurgery Quality Outcomes Database Registry. 
Neurosurgery 63 (Suppl 1):160, 2016 (Abstract 148)
 5. Cenic A, Kachur E: Lumbar discectomy: a national survey 
of neurosurgeons and literature review. Can J Neurol Sci 
36:196–200, 2009
 6. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new 
method of classifying prognostic comorbidity in longitudinal 
studies: development and validation. J Chronic Dis 40:373–
383, 1987
 7. Copay AG, Glassman SD, Subach BR, Berven S, Schuler TC, 
Carreon LY: Minimum clinically important difference in 
lumbar spine surgery patients: a choice of methods using the 
Oswestry Disability Index, Medical Outcomes Study ques-
tionnaire Short Form 36, and pain scales. Spine J 8:968–974, 
2008
 8. Davis R, Emmons SE: Benefits of epidural methylpredniso-
lone in a unilateral lumbar discectomy: a matched controlled 
study. J Spinal Disord 3:299–307, 1990
 9. Debi R, Halperin N, Mirovsky Y: Local application of ste-
roids following lumbar discectomy. J Spinal Disord Tech 
15:273–276, 2002
10. Delaney TJ, Rowlingson JC, Carron H, Butler A: Epidural 
steroid effects on nerves and meninges. Anesth Analg 
59:610–614, 1980
11. Deyo RA, Battie M, Beurskens AJ, Bombardier C, Croft P, 
Koes B, et al: Outcome measures for low back pain research. 
A proposal for standardized use. Spine (Phila Pa 1976) 
23:2003–2013, 1998
12. EuroQol Group: EuroQol—a new facility for the measure-
ment of health-related quality of life. Health Policy 16:199–
208, 1990
13. Fairbank JC, Couper J, Davies JB, O’Brien JP: The Oswes-
try low back pain disability questionnaire. Physiotherapy 
66:271–273, 1980
14. Foulkes GD, Robinson JS Jr: Intraoperative dexamethasone 
irrigation in lumbar microdiskectomy. Clin Orthop Relat 
Res (261):224–228, 1990
15. Gautschi OP, Corniola MV, Joswig H, Smoll NR, Chau I, 
Jucker D, et al: The timed up and go test for lumbar degen-
erative disc disease. J Clin Neurosci 22:1943–1948, 2015
16. Gautschi OP, Corniola MV, Schaller K, Smoll NR, Stienen 
MN: The need for an objective outcome measurement in 
spine surgery—the timed-up-and-go test. Spine J 14:2521–
2522, 2014
17. Gautschi OP, Corniola MV, Smoll NR, Joswig H, Schaller K, 
Hildebrandt G, et al: Sex differences in subjective and objec-
tive measures of pain, functional impairment, and health-
related quality of life in patients with lumbar degenerative 
disc disease. Pain 157:1065–1071, 2016
18. Gautschi OP, Joswig H, Corniola MV, Smoll NR, Schaller 
K, Hildebrandt G, et al: Pre- and postoperative correlation of 
patient-reported outcome measures with standardized Timed 
Up and Go (TUG) test results in lumbar degenerative disc 
disease. Acta Neurochir (Wien) 158:1875–1881, 2016
19. Gautschi OP, Smoll NR, Corniola MV, Joswig H, Chau I, Hil-
debrandt G, et al: Validity and reliability of a measurement of 
objective functional impairment in lumbar degenerative disc 
disease: the Timed Up and Go (TUG) Test. Neurosurgery 
79:270–278, 2016
20. Gautschi OP, Smoll NR, Joswig H, Corniola MV, Schaller K, 
Hildebrandt G, et al: Influence of age on pain intensity, func-
tional impairment and health-related quality of life before 
and after surgery for lumbar degenerative disc disease. Clin 
Neurol Neurosurg 150:33–39, 2016
21. Gautschi OP, Stienen MN, Corniola MV, Joswig H, Schaller 
K, Hildebrandt G, et al: Assessment of the minimum clini-
cally important difference in the timed up and go test after 
surgery for lumbar degenerative disc disease. Neurosurgery 
80:380–385, 2017
22. Green LN: Dexamethasone in the management of symptoms 
due to herniated lumbar disc. J Neurol Neurosurg Psychia-
try 38:1211–1217, 1975
23. Häckel M, Masopust V, Bojar M, Ghaly Y, Horínek D: The 
epidural steroids in the prevention of epidural fibrosis: MRI 
and clinical findings. Neuroendocrinol Lett 30:51–55, 2009
24. Häkkinen A, Kautiainen H, Järvenpää S, Arkela-Kautiainen 
M, Ylinen J: Changes in the total Oswestry Index and its ten 
items in females and males pre- and post-surgery for lumbar 
disc herniation: a 1-year follow-up. Eur Spine J 16:347–352, 
2007
25. Hurlbert RJ, Theodore N, Drabier JB, Magwood AM, 
Sonntag VK: A prospective randomized double-blind con-
trolled trial to evaluate the efficacy of an analgesic epidural 
paste following lumbar decompressive surgery. J Neurosurg 
90 (2 Suppl):191–197, 1999
26. Jamjoom BA, Jamjoom AB: Efficacy of intraoperative epi-
dural steroids in lumbar discectomy: a systematic review. 
BMC Musculoskelet Disord 15:146, 2014
27. Jirarattanaphochai K, Jung S, Thienthong S, Krisanapra-
kornkit W, Sumananont C: Peridural methylprednisolone and 
wound infiltration with bupivacaine for postoperative pain 
control after posterior lumbar spine surgery: a randomized 
double-blinded placebo-controlled trial. Spine (Phila Pa 
1976) 32:609–617, 2007
28. Jones KG, Barnett HC: The use of hydrocortisone in spinal 
surgery. South Med J 48:617–623, 1955
29. Keats AS: The ASA classification of physical status—a reca-
pitulation. Anesthesiology 49:233–236, 1978
30. Landriel Ibañez FA, Hem S, Ajler P, Vecchi E, Ciraolo C, 
Baccanelli M, et al: A new classification of complications in 
neurosurgery. World Neurosurg 75:709–715, 604–611, 2011
31. Lavyne MH, Bilsky MH: Epidural steroids, postoperative 
morbidity, and recovery in patients undergoing microsurgical 
lumbar discectomy. J Neurosurg 77:90–95, 1992
32. Lotfinia I, Khallaghi E, Meshkini A, Shakeri M, Shima M, 
Safaeian A: Interaoperative use of epidural methylpredniso-
lone or bupivacaine for postsurgical lumbar discectomy pain 
relief: a randomized, placebo-controlled trial. Ann Saudi 
Med 27:279–283, 2007
33. Lowell TD, Errico TJ, Eskenazi MS: Use of epidural steroids 
after discectomy may predispose to infection. Spine (Phila 
Pa 1976) 25:516–519, 2000
34. Lundin A, Magnuson A, Axelsson K, Kogler H, Samuelsson 
L: The effect of perioperative corticosteroids on the outcome 
of microscopic lumbar disc surgery. Eur Spine J 12:625–
630, 2003
35. Marshall LL, Trethewie ER: Chemical irritation of nerve-
root in disc prolapse. Lancet 2:320, 1973
36. McNeill TW, Andersson GB, Schell B, Sinkora G, Nelson J, 
Lavender SA: Epidural administration of methylprednisolone 
and morphine for pain after a spinal operation. A random-
ized, prospective, comparative study. J Bone Joint Surg Am 
77:1814–1818, 1995
37. Mirzai H, Tekin I, Alincak H: Perioperative use of corticoste-
roid and bupivacaine combination in lumbar disc surgery: a 
randomized controlled trial. Spine (Phila Pa 1976) 27:343–
346, 2002
38. Modic MT, Steinberg PM, Ross JS, Masaryk TJ, Carter JR: 
Intraoperative epidural steroid application in microdiscectomy
J Neurosurg Spine Volume 28 • March 2018 299
Degenerative disk disease: assessment of changes in vertebral 
body marrow with MR imaging. Radiology 166:193–199, 
1988
39. Mundry R, Nunn CL: Stepwise model fitting and statisti-
cal inference: turning noise into signal pollution. Am Nat 
173:119–123, 2009
40. Naylor A, Flowers MW, Bramley JE: The value of dexameth-
asone in the postoperative treatment of lumbar disc prolapse. 
Orthop Clin North Am 8:3–8, 1977
41. Nelson DA, Landau WM: Intraspinal steroids: history, ef-
ficacy, accidentality, and controversy with review of United 
States Food and Drug Administration reports. J Neurol Neu-
rosurg Psychiatry 70:433–443, 2001
42. Pfirrmann CW, Metzdorf A, Zanetti M, Hodler J, Boos N: 
Magnetic resonance classification of lumbar intervertebral 
disc degeneration. Spine (Phila Pa 1976) 26:1873–1878, 
2001
43. Ranguis SC, Li D, Webster AC: Perioperative epidural ste-
roids for lumbar spine surgery in degenerative spinal disease. 
A review. J Neurosurg Spine 13:745–757, 2010
44. Rasmussen S, Krum-Møller DS, Lauridsen LR, Jensen SE, 
Mandøe H, Gerlif C, et al: Epidural steroid following discec-
tomy for herniated lumbar disc reduces neurological impair-
ment and enhances recovery: a randomized study with two-
year follow-up. Spine (Phila Pa 1976) 33:2028–2033, 2008
45. Roland M, Fairbank J: The Roland-Morris Disability Ques-
tionnaire and the Oswestry Disability Questionnaire. Spine 
(Phila Pa 1976) 25:3115–3124, 2000
46. Shin SH, Hwang BW, Keum HJ, Lee SJ, Park SJ, Lee SH: 
Epidural steroids after a percutaneous endoscopic lumbar 
discectomy. Spine (Phila Pa 1976) 40:E859–E865, 2015
47. Stienen MN, Joswig H, Smoll NR, Corniola MV, Schaller K, 
Hildebrandt G, et al: Influence of body mass index on subjec-
tive and objective measures of pain, functional impairment 
and health-related quality of life in lumbar degenerative disc 
disease. World Neurosurg 96:570–577, 577.e1, 2016
48. Stienen MN, Joswig H, Smoll NR, Corniola MV, Schaller K, 
Hildebrandt G, et al: Short- and long-term outcome of mi-
croscopic lumbar spine surgery in patients with predominant 
back or predominant leg pain. World Neurosurg 93:458–
465, 465.e1, 2016
49. Stienen MN, Smoll NR, Hildebrandt G, Schaller K, Tessitore 
E, Gautschi OP: Constipation after thoraco-lumbar fusion 
surgery. Clin Neurol Neurosurg 126:137–142, 2014
50. Stienen MN, Smoll NR, Joswig H, Corniola MV, Schaller 
K, Hildebrandt G, et al: Validation of the baseline severity 
stratification of objective functional impairment in lumbar 
degenerative disc disease. J Neurosurg Spine 26:598–604, 
2017
51. Stratford PW, Binkley JM, Riddle DL, Guyatt GH: Sensitiv-
ity to change of the Roland-Morris Back Pain Questionnaire: 
part 1. Phys Ther 78:1186–1196, 1998
52. Than KD, Curran JN, Resnick DK, Shaffrey CI, Ghogawala 
Z, Mummaneni PV: How to predict return to work after lum-
bar discectomy: answers from the NeuroPoint-SD registry. J 
Neurosurg Spine 25:181–186, 2016
Disclosures 
The authors report no conflict of interest concerning the materi-
als or methods used in this study or the findings specified in this 
paper.
Author Contributions
Conception and design: Stienen, Gautschi. Acquisition of data: 
Stienen, Joswig, Chau, Gautschi. Analysis and interpretation of 
data: Stienen, Joswig, Neidert, Bellut, Wälchli, Gautschi. Drafting 
the article: Stienen. Critically revising the article: Joswig, Chau, 
Neidert, Bellut, Wälchli, Schaller, Gautschi. Reviewed submitted 
version of manuscript: Stienen. Approved the final version of the 
manuscript on behalf of all authors: Stienen. Statistical analysis: 
Stienen. Administrative/technical/material support: Schaller, 
Gautschi. Study supervision: Bellut, Schaller, Gautschi.
Correspondence
Martin N. Stienen, Department of Neurosurgery, University Hos-
pital Zürich, Frauenklinikstrasse 10, Zürich 8091, Switzerland. 
email: mnstienen@gmail.com.
